News stories about Protagonist Therapeutics (NASDAQ:PTGX) have trended somewhat positive on Friday, Accern reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Protagonist Therapeutics earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.0810863780726 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Several brokerages have recently commented on PTGX. ValuEngine raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 28th. BTIG Research initiated coverage on Protagonist Therapeutics in a research note on Friday, July 21st. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Zacks Investment Research raised Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Friday, August 18th.
Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.70).
In related news, insider Richard S. Shames sold 1,512 shares of the business’s stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $17.00, for a total value of $25,704.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Richard S. Shames sold 2,017 shares of the business’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $19.00, for a total transaction of $38,323.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,716 shares of company stock valued at $169,288.
TRADEMARK VIOLATION WARNING: “Protagonist Therapeutics (PTGX) Given Coverage Optimism Score of 0.08” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2956834/protagonist-therapeutics-ptgx-given-coverage-optimism-score-of-0-08.html.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.